<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121018">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01907971</url>
  </required_header>
  <id_info>
    <org_study_id>VentriPoint in Ebstein anomaly</org_study_id>
    <nct_id>NCT01907971</nct_id>
  </id_info>
  <brief_title>Assessment of Left and Right Ventricular Function in Patients With Ebstein Anomaly With Different Echocardiographic Methods</brief_title>
  <official_title>Left Ventricular Function in Ebstein Anomaly: Assessment by 3D Echocardiography and Speckle Tracking. Assessment and Validation of the Right Ventricle by VentriPoint Method.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angela Oxenius</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Children's Hospital, Zurich</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ebstein anomaly is a rare congenital heart disease. It encompasses abnormalities of the
      tricuspid valve, the right atrium and the right ventricle (RV).

      Currently, cardiac magnetic resonance imaging (MRI) is considered the method of choice for
      the assessment of RV volume and function. To evaluate the right heart function VentriPoint
      method was designed to assess the RV in a fraction of the time, resulting in better efficacy
      and lower costs. VentriPoint is approved for Tetralogy of Fallot patients as well as
      patients with systemic RV in d-transposition of the great arteries. This method uses 2
      dimensional standard ultrasound views linked to a VentriPoint Medical Systems unit. After
      acquisition, the physician identifies anatomical landmarks with dots on a number of the 2D
      ultrasound views through the heart. With a sensor (magnetic tracking system: GPS) on the
      ultrasound probe we know where the 2D plane is in 3D space. In this way the precise
      anatomical landmark is located in 3D space.

      The aim of the present study is to assess the feasibility, reliability and accuracy of the
      echocardiographic knowledge-based 3D reconstruction method to measure RV volume and function
      in patients with Ebstein anomaly. The accuracy of the method will be assessed by comparison
      with measurements obtained by cardiac MRI.

      In addition to the right ventricle the investigators want to assess the left ventricular
      function in patients with Ebstein anomaly in this study. By using speckle tracking
      echocardiography the investigators would like to investigate on the left ventricular
      contractility, rotation and synchrony of the left ventricle together with the RV. Not seldom
      the left ventricle is neglected in a patient with Ebstein anomaly by impressive findings of
      the right ventricle. Changes in the myocardial left ventricular structure (non compaction)
      are also described and may have negative impact on the function.

      The investigators want to analyze 25-30 patients with Ebstein anomaly including children
      starting at 11 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Right ventricular volume (ml/m2) and function by VentriPoint. Structural myocardial changes in the left ventricle (Strain).</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the VentriPoint findings with measurements obtained by cardiac MRI.
Structural changes of the left ventricle by echocardiography as well as ventricular longitudinal deformation in strain value by speckle tracking echocardiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of findings with clinical symptoms</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation with the severity of tricuspid regurgitation, the clinical symptoms, size and function of the right ventricle</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Ebstein Anomaly</condition>
  <arm_group>
    <arm_group_label>Ebstein anomaly</arm_group_label>
    <description>Patients with Ebstein anomaly</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Ebstein anomaly patients of the Zurich Area followed by primary care center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ebstein anomaly

          -  male and female 11 years to 80 years of age

          -  Unoperated or operated on the heart, including 1 1/2 chamber palliation

          -  Wolff-Parkinson-White Syndrome

        Exclusion Criteria:

          -  moderate or severe mitral valve insufficiency, moderate or severe aortic
             insufficiency, moderate or severe aortic stenosis

          -  Univentricular palliation (Fontan)

          -  St.n. myectomy of the left ventricle

          -  Concomitant L-transposition of the great arteries
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine H Attenhofer, Prof</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Angela Oxenius, MD</last_name>
    <phone>+41 44 266 73 27</phone>
    <email>angela.oxenius@kispi.uzh.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland Weber, MD</last_name>
    <phone>+41 44 266 80 96</phone>
    <email>roland.weber@kispi.uzh.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Oxenius, MD</last_name>
      <phone>+41 44 266 73 23</phone>
      <email>angela.oxenius@kispi.uzh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Roland W Weber, MD</last_name>
      <phone>+41 44 266 80 96</phone>
      <email>roland.weber@kispi.uzh.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Christine H Attenhofer, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Oxenius, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland W Weber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Childrens Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Oxenius, MD</last_name>
      <phone>+41 44 266 73 27</phone>
      <email>angela.oxenius@kispi.uzh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Roland W Weber, MD</last_name>
      <phone>+41 44 266 80 96</phone>
      <email>roland.weber@kispi.uzh.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Christine H Attenhofer, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Oxenius, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland W Weber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ventripoint.com</url>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>July 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Children's Hospital, Zurich</investigator_affiliation>
    <investigator_full_name>Angela Oxenius</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Ebstein Anomaly</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
